Oxford Biomedica plc, a gene and cell therapy group, has signed a new License and Supply Agreement (LSA) with an undisclosed U.S.-based late-stage cell and gene therapy company, granting the new partner a non-exclusive license to utilize Oxford Biomedica’s LentiVector platform for its application in their lead program, a cell-based therapy targeting a rare indication, putting into place a five-year clinical supply arrangement.   Under the terms of the LSA, Oxford Biomedica will receive an undi...